Analyst Viewpoint
Increase in number of road accidents due to growth in traffic and availability of medical facilities in emergencies is fostering the thrombin market growth. Thrombin helps control heavy blood loss during surgeries, thereby allowing surgeons to operate patients efficiently. Furthermore, increase in prevalence of inherited blood coagulation diseases is driving the demand for thrombin. Healthcare professionals prefer thrombin due to its procoagulant properties.
Rise in R&D activities in the pharmaceutical sector for drug development to treat inherited blood-related disorders and government initiatives to improve availability of medical facilities in developing regions are generating lucrative thrombin market opportunities. Leading players in the market are focusing on new drug development strategies to meet the surge in demand for thrombin from healthcare organizations.
Thrombin is a serine protease blood plasma protein used to convert fibrinogen to soluble fibrin. Thrombin helps catalyze the blood coagulation process with its unique molecule functions; as a procoagulant, it activates platelets through its receptor on platelets. Thrombin is used to control excessive bleeding and clotting during medical surgeries. Additionally, thrombin is used in diagnostic centers & clinics in several applications, such as coagulation assays, defibrination of blood or plasma, and clotting factor tests.
Bovine thrombin, human thrombin, and recombinant thrombin are major types of thrombin utilized in medical surgeries and diagnostic centers. Bovine thrombin is an enzyme that converts fibrinogen to fibrin. It is used in the defibrination of plasma to produce serum matrixes to be used as standards and controls. Human thrombin is a sterile solution containing highly purified human thrombin to activate clotting. Human thrombin is indicated as an aid to hemostasis during minor bleeding from small venules and capillaries.
Thrombin is employed to control excessive blood flow during complex surgeries to treat severe injuries and trauma. Increase in number of road accidents and injuries is fueling market statistics. Thrombin is utilized in safer hemostatic conditions and postoperative complications to ensure faster recovery from traumas. Road accidents are increasing due to the negligence on roads and non-adherence to road safety rules. According to the thrombin market forecast, growth in hospitalizations due to road accidents is projected to fuel market development.
According to the World Health Organization, every year around 1.3 billion people die due to road traffic crashes. Approximately 20 to 50 million people suffer from non-fatal injuries, with many incurring a disability. Increase in investments by governments for quick hospitalization post-accidents is increasing the number of surgeries, thereby driving the use of thrombin.
Companies in the drug development industry are investing in research and development activities to provide appropriate treatments for blood-related diseases or disorders. Thrombin is a crucial element used to treat several blood coagulation disorders, such as Von Willebrand disease, hypercoagulable states, hemophilia, and deep venous thrombosis. Increase in R&D activities by companies operating in the pharmaceutical sector to launch new drugs for these disorders is boosting the thrombin market revenue.
Vitro study, protein-structure analysis, coagulation research, and medical & biochemical research are ongoing market trends in bovine-derived thrombin products. Rise in demand for bovine thrombin in the diagnostics sector for clotting factor tests, coagulation assays, and defibrination of blood or plasma, is fueling market dynamics.
As per the thrombin market analysis, North America accounted for largest share in 2022. Road safety concerns due to growth in traffic across the region is likely to increase the number of accidents that occur due to lack of traffic management. Well-established healthcare infrastructure in the region ensures immediate treatment and easy access to required medical facilities in case of emergencies. Thus, growth in number of road accidents and availability of treatment options are major factors bolstering the thrombin industry share. As per data published by Forbes, a total of 35,766 fatal car accidents occurred on roadways in the United States in 2020. Another 1,593,390 accidents resulted in injuries leading to severe disabilities among people.
Furthermore, increase in prevalence of inherited blood disorders, such as hemophilia, is propelling the market value. According to the World Federation of Hemophilia, approximately 11,790 patients with Hemophilia A and 3,026 patients with Hemophilia B were diagnosed in the United States in 2020.
Partnerships, new product launches, innovation in production lines, and research & development activities are major strategies adopted by leading market players. Capabilities to invest in innovative product development methodologies allow companies to deliver high-quality and efficient treatment to patients. Pharmaceutical companies invest substantially in conducting clinical trials to ensure efficiency of drugs and evaluate correct dosage according to the severity of disease and the patient’s condition.
Some of the leading companies in the industry are Johnson & Johnson, Pfizer, Inc., Mallinckrodt Pharmaceuticals, Shanghai RAAS Blood Products Co., Ltd., Japan Blood Products Organization, Mochida Pharmaceutical Co., Ltd., BIOFAC A/S, Biomed-Lublin S.A., and Hualan Biological Engineering, Inc.
These companies are profiled in the thrombin market report based on parameters such as company overview, financial overview, business segments, product portfolio, business strategies, and key developments.
| Attribute | Detail |
|---|---|
| Market Size in 2022 | US$ 652.2 Mn |
| Market Forecast (Value) in 2031 | US$ 1.1 Bn |
| Growth Rate (CAGR) | 6.1% |
| Forecast Period | 2023-2031 |
| Historical Data Available for | 2017-2021 |
| Quantitative Tons | US$ Bn/Mn for Value |
| Market Analysis | It includes segment analysis as well as regional level analysis. Furthermore, qualitative analysis includes drivers, restraints, opportunities, key trends, Porter’s Five Forces Analysis, value chain analysis, and key trend analysis. |
| Competition Landscape |
|
| Format | Electronic (PDF) + Excel |
| Market Segmentation |
|
| Regions Covered |
|
| Countries Covered |
|
| Companies Profiled |
|
| Customization Scope | Available upon request |
| Pricing | Available upon request |
It was valued at US$ 652.2 Mn in 2022
It is projected to register a CAGR of 6.1% from 2023 to 2031
Increase in number of road accidents and growth in R&D activities in the pharmaceutical sector
North America was the most lucrative region in 2022
Johnson & Johnson, Pfizer, Inc., Mallinckrodt Pharmaceuticals, Shanghai RAAS Blood Products Co., Ltd., Japan Blood Products Organization, Mochida Pharmaceutical Co., Ltd., BIOFAC A/S, Biomed-Lublin S.A., and Hualan Biological Engineering, Inc.
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Thrombin Market
4. Market Overview
4.1. Introduction
4.1.1. Product Definition
4.1.2. Industry Evolution / Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Thrombin Market Analysis and Forecasts, 2023–2031
5. Key Insights
5.1. Current Trends in Thrombin
5.2. Technological advancements in Thrombin
5.3. COVID-19 Impact Analysis
6. Global Thrombin Market Analysis and Forecasts, by Product
6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Market Value Forecast, by Product, 2023–2031
6.3.1. Bovine Thrombin
6.3.2. Human Thrombin
6.3.3. Recombinant Thrombin
6.4. Market Attractiveness Analysis, by Product
7. Global Thrombin Market Analysis and Forecasts, by Dosage Form
7.1. Introduction & Definition
7.2. Key Findings / Developments
7.3. Market Value Forecast, by Dosage Form, 2023–2031
7.3.1. Powder Form
7.3.2. Solution Form
7.3.3. Others
7.4. Market Attractiveness Analysis, by Dosage Form
8. Global Thrombin Market Analysis and Forecasts, by End-user
8.1. Introduction & Definition
8.2. Key Findings / Developments
8.3. Market Value Forecast, by End-user, 2023–2031
8.3.1. Hospitals
8.3.2. Diagnostic Centers & Clinics
8.3.3. Academic & Research Institutes
8.4. Market Attractiveness Analysis, by End-user
9. Global Thrombin Market Analysis and Forecasts, by Region
9.1. Key Findings
9.2. Market Value Forecast, by Region
9.2.1. North America
9.2.2. Europe
9.2.3. Asia Pacific
9.2.4. Latin America
9.2.5. Middle East & Africa
9.3. Market Attractiveness Analysis, by Region
10. North America Thrombin Market Analysis and Forecast
10.1. Introduction
10.1.1. Key Findings
10.2. Market Value Forecast, by Product, 2023–2031
10.2.1. Bovine Thrombin
10.2.2. Human Thrombin
10.2.3. Recombinant Thrombin
10.3. Market Value Forecast, by Dosage Form, 2023–2031
10.3.1. Powder Form
10.3.2. Solution Form
10.3.3. Others
10.4. Market Value Forecast, by End-user, 2023–2031
10.4.1. Hospitals
10.4.2. Diagnostic Centers & Clinics
10.4.3. Academic & Research Institutes
10.5. Market Value Forecast, by Country, 2023–2031
10.5.1. U.S.
10.5.2. Canada
10.6. Market Attractiveness Analysis
10.6.1. By Product
10.6.2. By Dosage Form
10.6.3. By End-user
10.6.4. By Country
11. Europe Thrombin Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Market Value Forecast, by Product, 2023–2031
11.2.1. Bovine Thrombin
11.2.2. Human Thrombin
11.2.3. Recombinant Thrombin
11.3. Market Value Forecast, by Dosage Form, 2023–2031
11.3.1. Powder Form
11.3.2. Solution Form
11.3.3. Others
11.4. Market Value Forecast, by End-user, 2023–2031
11.4.1. Hospitals
11.4.2. Diagnostic Centers & Clinics
11.4.3. Academic & Research Institutes
11.5. Market Value Forecast, by Country/Sub-region, 2023–2031
11.5.1. Germany
11.5.2. U.K.
11.5.3. France
11.5.4. Italy
11.5.5. Spain
11.5.6. Rest of Europe
11.6. Market Attractiveness Analysis
11.6.1. By Product
11.6.2. By Dosage Form
11.6.3. By End-user
11.6.4. By Country/Sub-region
12. Asia Pacific Thrombin Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast, by Product, 2023–2031
12.2.1. Bovine Thrombin
12.2.2. Human Thrombin
12.2.3. Recombinant Thrombin
12.3. Market Value Forecast, by Dosage Form, 2023–2031
12.3.1. Powder Form
12.3.2. Solution Form
12.3.3. Others
12.4. Market Value Forecast, by End-user, 2023–2031
12.4.1. Hospitals
12.4.2. Diagnostic Centers & Clinics
12.4.3. Academic & Research Institutes
12.5. 12.5. Market Value Forecast, by Country/Sub-region, 2023–2031
12.5.1. China
12.5.2. India
12.5.3. Japan
12.5.4. Australia & New Zealand
12.5.5. Rest of Asia Pacific
12.6. Market Attractiveness Analysis
12.6.1. By Product
12.6.2. By Dosage Form
12.6.3. By End-user
12.6.4. By Country/Sub-region
13. Latin America Thrombin Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast, by Product, 2023–2031
13.2.1. Bovine Thrombin
13.2.2. Human Thrombin
13.2.3. Recombinant Thrombin
13.3. Market Value Forecast, by Dosage Form, 2023–2031
13.3.1. Powder Form
13.3.2. Solution Form
13.3.3. Others
13.4. Market Value Forecast, by End-user, 2023–2031
13.4.1. Hospitals
13.4.2. Diagnostic Centers & Clinics
13.4.3. Academic & Research Institutes
13.5. Market Value Forecast, by Country/Sub-region, 2023–2031
13.5.1. Brazil
13.5.2. Mexico
13.5.3. Rest of Latin America
13.6. Market Attractiveness Analysis
13.6.1. By Product
13.6.2. By Dosage Form
13.6.3. By End-user
13.6.4. By Country/Sub-region
14. Middle East & Africa Thrombin Market Analysis and Forecast
14.1. Introduction
14.1.1. Key Findings
14.2. Market Value Forecast, by Product, 2023–2031
14.2.1. Bovine Thrombin
14.2.2. Human Thrombin
14.2.3. Recombinant Thrombin
14.3. Market Value Forecast, by Dosage Form, 2023–2031
14.3.1. Powder Form
14.3.2. Solution Form
14.3.3. Others
14.4. Market Value Forecast, by End-user, 2023–2031
14.4.1. Hospitals
14.4.2. Diagnostic Centers & Clinics
14.4.3. Academic & Research Institutes
14.5. Market Value Forecast, by Country/Sub-region, 2023–2031
14.5.1. GCC Countries
14.5.2. South Africa
14.5.3. Rest of Middle East & Africa
14.6. Market Attractiveness Analysis
14.6.1. By Product
14.6.2. By Dosage Form
14.6.3. By End-user
14.6.4. By Country/Sub-region
15. Competition Landscape
15.1. Market Player – Competition Matrix (By Tier and Size of companies)
15.2. Market Share Analysis, by Company (2022)
15.3. Company Profiles
15.3.1. Johnson & Johnson
15.3.1.1. Company Overview
15.3.1.2. Financial Overview
15.3.1.3. Product Portfolio
15.3.1.4. Strategic Overview
15.3.1.5. SWOT Analysis
15.3.2. Pfizer, Inc.
15.3.2.1. Company Overview
15.3.2.2. Financial Overview
15.3.2.3. Product Portfolio
15.3.2.4. Strategic Overview
15.3.2.5. SWOT Analysis
15.3.3. Mallinckrodt Pharmaceuticals
15.3.3.1. Company Overview
15.3.3.2. Financial Overview
15.3.3.3. Product Portfolio
15.3.3.4. Strategic Overview
15.3.3.5. SWOT Analysis
15.3.4. Shanghai RAAS Blood Products Co., Ltd.
15.3.4.1. Company Overview
15.3.4.2. Financial Overview
15.3.4.3. Product Portfolio
15.3.4.4. Strategic Overview
15.3.4.5. SWOT Analysis
15.3.5. Japan Blood Products Organization
15.3.5.1. Company Overview
15.3.5.2. Financial Overview
15.3.5.3. Product Portfolio
15.3.5.4. Strategic Overview
15.3.5.5. SWOT Analysis
15.3.6. Mochida Pharmaceutical Co., Ltd.
15.3.6.1. Company Overview
15.3.6.2. Financial Overview
15.3.6.3. Product Portfolio
15.3.6.4. Strategic Overview
15.3.6.5. SWOT Analysis
15.3.7. BIOFAC A/S
15.3.7.1. Company Overview
15.3.7.2. Financial Overview
15.3.7.3. Product Portfolio
15.3.7.4. Strategic Overview
15.3.7.5. SWOT Analysis
15.3.8. Biomed-Lublin S.A.
15.3.8.1. Company Overview
15.3.8.2. Financial Overview
15.3.8.3. Product Portfolio
15.3.8.4. Strategic Overview
15.3.8.5. SWOT Analysis
15.3.9. Hualan Biological Engineering, Inc.
15.3.9.1. Company Overview
15.3.9.2. Financial Overview
15.3.9.3. Product Portfolio
15.3.9.4. Strategic Overview
15.3.9.5. SWOT Analysis
List of Tables
Table 01: Global Thrombin Market Value (US$ Mn) Forecast, by Product, 2023–2031
Table 02: Global Thrombin Market Value (US$ Mn) Forecast, by Dosage Form, 2023–2031
Table 03: Global Thrombin Market Value (US$ Mn) Forecast, by End-user, 2023–2031
Table 04: Global Thrombin Market Value (US$ Mn) Forecast, by Region, 2023–2031
Table 05: North America Thrombin Market Value (US$ Mn) Forecast, by Product, 2023–2031
Table 06: North America Thrombin Market Value (US$ Mn) Forecast, by Dosage Form, 2023–2031
Table 07: North America Thrombin Market Value (US$ Mn) Forecast, by End-user, 2023–2031
Table 08: North America Thrombin Market Value (US$ Mn) Forecast, by Country, 2023–2031
Table 09: Europe Thrombin Market Value (US$ Mn) Forecast, by Product, 2023–2031
Table 10: Europe Thrombin Market Value (US$ Mn) Forecast, by Dosage Form, 2023–2031
Table 11: Europe Thrombin Market Value (US$ Mn) Forecast, by End-user, 2023–2031
Table 12: Europe Thrombin Market Value (US$ Mn) Forecast, by Country/Sub-region, 2023–2031
Table 13: Asia Pacific Thrombin Market Value (US$ Mn) Forecast, by Product, 2023–2031
Table 14: Asia Pacific Thrombin Market Value (US$ Mn) Forecast, by Dosage Form, 2023–2031
Table 15: Asia Pacific Thrombin Market Value (US$ Mn) Forecast, by End-user, 2023–2031
Table 16: Asia Pacific Thrombin Market Value (US$ Mn) Forecast, by Country/Sub-region, 2023–2031
Table 17: Latin America Thrombin Market Value (US$ Mn) Forecast, by Product, 2023–2031
Table 18: Latin America Thrombin Market Value (US$ Mn) Forecast, by Dosage Form, 2023–2031
Table 19: Latin America Thrombin Market Value (US$ Mn) Forecast, by End-user, 2023–2031
Table 20: Latin America Thrombin Market Value (US$ Mn) Forecast, by Country/Sub-region, 2023–2031
Table 21: Middle East & Africa Thrombin Market Value (US$ Mn) Forecast, by Product, 2023–2031
Table 22: Middle East & Africa Thrombin Market Value (US$ Mn) Forecast, by Dosage Form, 2023–2031
Table 23: Middle East & Africa Thrombin Market Value (US$ Mn) Forecast, by End-user, 2023–2031
Table 24: Middle East & Africa Thrombin Market Value (US$ Mn) Forecast, by Country/Sub-region, 2023–2031
List of Figures
Figure 01: Global Thrombin Market Value (US$ Mn) Forecast, 2023–2031
Figure 02: Global Thrombin Market Value Share Analysis, by Product, 2022 and 2031
Figure 03: Global Thrombin Market Attractiveness Analysis, by Product, 2023–2031
Figure 04: Global Thrombin Market Value Share Analysis, by Dosage Form 2022 and 2031
Figure 05: Global Thrombin Market Attractiveness Analysis, by Dosage Form, 2023–2031
Figure 06: Global Thrombin Market Value Share Analysis, by End-user, 2022 and 2031
Figure 07: Global Thrombin Market Attractiveness Analysis, by End-user, 2023–2031
Figure 08: Global Thrombin Market Value Share Analysis, by Region, 2022 and 2031
Figure 09: Global Thrombin Market Attractiveness Analysis, by Region, 2023–2031
Figure 10: North America Thrombin Market Value (US$ Mn) Forecast, 2023–2031
Figure 11: North America Thrombin Market Value Share Analysis, by Product, 2022 and 2031
Figure 12: North America Thrombin Market Attractiveness Analysis, by Product, 2023–2031
Figure 13: North America Thrombin Market Value Share Analysis, by Dosage Form, 2022 and 2031
Figure 14: North America Thrombin Market Attractiveness Analysis, by Dosage Form, 2023–2031
Figure 15: North America Thrombin Market Value Share Analysis, by End-user, 2022 and 2031
Figure 16: North America Thrombin Market Attractiveness Analysis, by End-user, 2023–2031
Figure 17: North America Thrombin Market Value Share Analysis, by Country, 2022 and 2031
Figure 18: North America Thrombin Market Attractiveness Analysis, by Country, 2023–2031
Figure 19: Europe Thrombin Market Value (US$ Mn) Forecast, 2023–2031
Figure 20: Europe Thrombin Market Value Share Analysis, by Product, 2022 and 2031
Figure 21: Europe Thrombin Market Attractiveness Analysis, by Product, 2023–2031
Figure 22: Europe Thrombin Market Value Share Analysis, by Dosage Form, 2022 and 2031
Figure 23: Europe Thrombin Market Attractiveness Analysis, by Dosage Form, 2023–2031
Figure 24: Europe Thrombin Market Value Share Analysis, by End-user, 2022 and 2031
Figure 25: Europe Thrombin Market Attractiveness Analysis, by End-user, 2023–2031
Figure 26: Europe Thrombin Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
Figure 27: Europe Thrombin Market Attractiveness Analysis, by Country/Sub-region, 2023–2031
Figure 28: Asia Pacific Thrombin Market Value (US$ Mn) Forecast, 2023–2031
Figure 29: Asia Pacific Thrombin Market Value Share Analysis, by Product, 2022 and 2031
Figure 30: Asia Pacific Thrombin Market Attractiveness Analysis, by Product, 2023–2031
Figure 31: Asia Pacific Thrombin Market Value Share Analysis, by Dosage Form 2022 and 2031
Figure 32: Asia Pacific Thrombin Market Attractiveness Analysis, by Dosage Form, 2023–2031
Figure 33: Asia Pacific Thrombin Market Value Share Analysis, by End-user, 2022 and 2031
Figure 34: Asia Pacific Thrombin Market Attractiveness Analysis, by End-user, 2023–2031
Figure 35: Asia Pacific Thrombin Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
Figure 36: Asia Pacific Thrombin Market Attractiveness Analysis, by Country/Sub-region, 2023–2031
Figure 37: Latin America Thrombin Market Value (US$ Mn) Forecast, 2023–2031
Figure 38: Latin America Thrombin Market Value Share Analysis, by Product, 2022 and 2031
Figure 39: Latin America Thrombin Market Attractiveness Analysis, by Product, 2023–2031
Figure 40: Latin America Thrombin Market Value Share Analysis, by Dosage Form, 2022 and 2031
Figure 41: Latin America Thrombin Market Attractiveness Analysis, by Dosage Form, 2023–2031
Figure 42: Latin America Thrombin Market Value Share Analysis, by End-user, 2022 and 2031
Figure 43: Latin America Thrombin Market Attractiveness Analysis, by End-user, 2023–2031
Figure 44: Latin America Thrombin Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
Figure 45: Latin America Thrombin Market Attractiveness Analysis, by Country/Sub-region, 2023–2031
Figure 46: Middle East & Africa Thrombin Market Value (US$ Mn) Forecast, 2023–2031
Figure 47: Middle East & Africa Thrombin Market Value Share Analysis, by Product, 2022 and 2031
Figure 48: Middle East & Africa Thrombin Market Attractiveness Analysis, by Product, 2023–2031
Figure 49: Middle East & Africa Thrombin Market Value Share Analysis, by Dosage Form, 2022 and 2031
Figure 50: Middle East & Africa Thrombin Market Attractiveness Analysis, by Dosage Form, 2023–2031
Figure 51: Middle East & Africa Thrombin Market Value Share Analysis, by End-user, 2022 and 2031
Figure 52: Middle East & Africa Thrombin Market Attractiveness Analysis, by End-user, 2023–2031
Figure 53: Middle East & Africa Thrombin Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
Figure 54: Middle East & Africa Thrombin Market Attractiveness Analysis, by Country/Sub-region, 2023–2031
Figure 55: Global Thrombin Market Share Analysis, by Company, 2022
Copyright © Transparency Market Research, Inc. All Rights reserved
Trust Online
Thrombin Market
